Building a medtech brand?
We run PR and public affairs for companies in this market: from category launches and funding announcements to NHS procurement and regulatory communications.
Owlstone Medical
Breath biopsy diagnostics
Diagnostics & imaging
Cambridge diagnostics company building breath-based tests, its Breath Biopsy platform, to detect cancer and other diseases from volatile organic compounds on a patient's breath.
The read
Owlstone Medical's Breath Biopsy platform analyses volatile organic compounds in exhaled breath to detect disease non-invasively, targeting lung cancer, liver disease and digestive conditions, and is offered to academic, clinical and pharma partners developing their own breath-based diagnostics rather than sold as a single finished test.
In October 2025 it secured a $49.1m grant from the US government's ARPA-H agency for its POSEIDON programme, developing synthetic-sensor multi-cancer early detection tests capable of screening for more than 30 solid tumours from a single breath sample, alongside a January 2025 Series E first close backed by the Gates Foundation.
The Bridgehead view
Owlstone's pivot toward US federal research funding, an ARPA-H grant nearly double its most recent equity round, is a reminder that for genuinely early-stage diagnostic science, government research money can be a more reliable growth lever than venture capital, and a different PR narrative to tell than a typical funding-round story.
Work with us
Working across the healthcare sector?
We advise NHS-facing organisations, providers and health systems on reputation, policy engagement and communications that understand the sector.
The firm that knows medtech
We map this sector because
we represent it.
Whether you build medical technology or run the health systems that buy it, we know the market, the media and the regulatory landscape it operates in. Thirty minutes with a partner tells you if we can help.
